[{"orgOrder":0,"company":"Arranta Bio","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Microbiome Therapeutic","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Arranta Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Arranta Bio \/ Recipharm","highestDevelopmentStatusID":"1","companyTruncated":"Arranta Bio \/ Recipharm"}]

Find Clinical Drug Pipeline Developments & Deals by Arranta Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The acquisition of Recipharm, to provide innovative drug developers in the Biologics market with differentiated contract development and manufacturing services for ATMPs and builds on the capabilities acquired through GenIbet transaction and acquisition ...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 18, 2022

                          Lead Product(s) : Microbiome Therapeutic

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Recipharm AB

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank